

**FindLaw**  
Legal News and Commentary  
<http://news.findlaw.com>

Mar. 28, 2003

**FindLaw**  
Free Court Forms

Type:

Direct from our site:



  
**PR Newswire**  
United Business Media

## **diaDexus Will Supply Analyte Specific Reagents\* for Use in a Test to Measure Lp-PLA2 in Blood**

SOUTH SAN FRANCISCO, Calif., Mar. 28 /PRNewswire/ --

SOUTH SAN FRANCISCO, Calif., March 28 /PRNewswire/ -- diaDexus, Inc., a privately held biotechnology company based in South San Francisco, today announced it will be providing analyte specific reagents to Mayo Medical Laboratories. Mayo will use these reagents to develop a test for the quantitative measurement of lipoprotein-associated phospholipase A2 (Lp-PLA2) in blood.

Mayo Medical Laboratories is the international reference laboratory for Mayo Clinic. diaDexus is providing the analyte specific reagents for Mayo to offer an Lp-PLA2 test to its laboratory customers. Last year, diaDexus, Mayo Clinic and Mayo Medical Laboratories initiated a partnership to investigate potential clinical applications of an Lp-PLA2 test.

"Our collaboration with Mayo has allowed our teams to work together on exploratory studies to better understand the clinical applications of Lp-PLA2," said Patrick Plewman, chief executive officer of diaDexus.

In February 2003, diaDexus submitted a 510(k) pre-market notification to the U.S. Food and Drug Administration seeking marketing clearance for the PLAC(TM) test as an in vitro diagnostic product to be used as a predictor of risk for coronary heart disease.

### **About diaDexus**

diaDexus, Inc., a privately held biotechnology company based in South San Francisco, Calif., is focused on the discovery, development, and commercialization of novel, patent-protected diagnostic and therapeutic products with high clinical value. diaDexus utilizes genomics and bioinformatics to identify disease-associated molecular targets. More information about the company may be found at <http://www.diadexus.com/>.

\*Analyte Specific Reagent. Analytical and performance characteristics have not been established.

This information concerns a use that has not been approved or cleared by the Food and Drug Administration. The information is being disseminated at the expense of the manufacturer.

diaDexus, Inc.

CONTACT: Sharon Tetlow of diaDexus, Inc., +1-650-246-6400, or  
Tama Antonia Donaldson of Dorland Global Health Communications

[http://news.findlaw.com/scripts/prnter\\_friendly.pl?page=/prnewsw.../28mar2003223647.htm](http://news.findlaw.com/scripts/prnter_friendly.pl?page=/prnewsw.../28mar2003223647.htm) 6/13/2003

PM3006731356

For more information, contact diaDexus, Inc. at 1-415-262-5206, for diaDexus, Inc.

Web site: <http://www.diadexus.com/>

---

[Company](#) | [Privacy Policy](#) | [Disclaimer](#)

Copyright © 1994-2001 FindLaw